Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 28, Issue , 2017, Pages iv1-iv21

  Postmus, P E ^a   Kerr, K M ^b   Oudkerk, M ^c   Senan, S ^d   Waller, D A ^e   Vansteenkiste, J ^f   Escriu, C ^a   Peters, S ^g  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE SYSTEM; HUMAN; LOW DOSE COMPUTED TOMOGRAPHY; LUNG DIFFUSION CAPACITY; LUNG LOBECTOMY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; EARLY CANCER DIAGNOSIS; LUNG TUMOR; ONCOLOGY; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY;

EID: 85029726749     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx222     Document Type: Article

References (139)

1. Centers for Disease Control and Prevention, Lung Cancer. https://www. cdc.gov/cancer/lung/basic_info/ (18 May 2017, date last accessed)
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007; 7: 778-790
3. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med 2011; 365: 395-409
4. Veronesi G, Maisonneuve P, Bellomi M et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012; 157: 776-784
5. Patz EF Jr, Pinsky P, Gatsonis C et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-274
6. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285
7. Franklin WA, Merrick DT, Achcar RD, Aberle DR. Reclassification of lung cancers detected by CT imaging in the American College of Radiology Imaging Network National Lung Screening Trial. J Thor Oncol 2015; 10 (9, Suppl 2): S220. oral24.05
8. Wiener RS, Gould MK, Arenberg DA et al. An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit CareMed 2015; 192: 881-891
9. Begnaud A, Hall T, Allen T. Lung cancer screening with low-dose CT: implementation amid changing public policy at one health care system. Am Soc Clin Oncol Educ Book 2016; 35: e468-e475
10. van Iersel CA, de Koning HJ, Draisma G et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multislice CT screening trial (NELSON). Int J Cancer 2007; 120: 868-874
11. Horeweg N, van Rosmalen J, Heuvelmans MA et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 2014; 15: 1332-1341
12. Walter JE, Heuvelmans MA, de Jong PA et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with lowdose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol 2016; 17: 907-916
13. Yousaf-Khan U, van der Aalst C, de Joing PA et al. Risk stratification based on screening history: the NELSON lung cancer screening study. Thorax 2017; 72: 48-56
14. Novello S, Barlesi F, Califano R et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl 5): v1-v27
15. Navani N, Brown JN, Nankivell M et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer. Am J Respir Crit Care Med 2012; 185: 1316-1322
16. Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization Classification of Lung Tumours: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thor Oncol 2015; 10: 1243-1260
17. Warth A, Muley T, Meister M et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012; 30: 1438-1446
18. Hung JJ, Yeh YC, Jeng WJ et al. Predictive value of the International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 2014; 32: 2357-2364
19. Tsao MS, Marguet S, Le Teuff G et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 2015; 33: 3439-3446
20. Yu Y, Jian H, Shen L et al. Lymph node involvement influenced by lung adenocarcinoma subtypes in tumour size ≤ 3 cm disease: a study of 2268 cases. Eur J Surg Oncol 2016; 42: 1714-1719
21. Liu S, Wang R, Zhang Y et al. Precise diagnosis of intraoperative frozen section is an effective method to guide resection strategy for peripheral small-sized lung adenocarcinoma. J Clin Oncol 2016; 34: 307-313
22. Walts AE, Marchevsky AM. Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung. Arch Pathol Lab Med 2012; 136: 1515-1521
23. Yeh YC, Nitadori J, Kadota K et al. Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤3 cm: accuracy and interobserver agreement. Histopathology 2015; 66: 922-938
24. Donington JS. An additional step toward personalization of surgical care for early-stage non-small-cell lung cancer. J Clin Oncol 2016; 34: 295-296
25. Nakamura H, Saji H, Marushima H et al. Standardized uptake values in the primary lesions of non-small-cell lung cancer in FDG-PET/CT can predict regional lymph nodemetastases. Ann Surg Oncol 2015; 22: S1388-S1393
26. Matsuzawa R, Kirita K, Kuwata T et al. Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma. Lung Cancer 2016; 94: 1-6
27. Callister ME, Baldwin DR, Akram AR et al. British Thoracic Society Guidelines for the investigation and management of pulmonary nodules. Thorax 2015; 70: ii1-ii54
28. MacMahon H, Naidich P, Goo JM et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017; 284: 228-243
29. Bai C, Choi CM, Chu CM et al. Evaluation of pulmonary nodules: clinical practice consensus guidelines for Asia. Chest 2016; 150: 877-893
30. Brierley JD, Gospodarowicz MK and Wittekind C. (eds). TNM Classification of Malignant Tumours, 8th edition. Oxford: John Wiley & Sons, Inc. 2016
31. Rami-Porta R, Bolejack V, Crowley J et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thor Oncol 2015; 10: 990-1003
32. Travis WD, Asamura H, Bankier AA et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2016; 11: 1204-1223
33. Detterbeck FC, Bolejack V, Arenberg DA et al. The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming edition of the TNM classification for lung cancer. J Thor Oncol 2016; 11: 681-692
34. Detterbeck FC, Franklin WA, Nicholson AG et al. The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thor Oncol 2016; 11: 651-665
35. Detterbeck FC, Nicholson AG, Franklin WA et al. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thor Oncol 2016; 11: 639-650
36. Detterbeck FC, Marom EM, Arenberg DA et al. The IASLC lung cancer staging project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification for lung cancer. J Thor Oncol 2016; 11: 666-680
37. Vilmann P, Clementsen PF, Colella S et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy 2015; 47: 545-559
38. Asamura H, Chansky C, Crowley J et al. The IASLC lung cancer staging project: proposals for the revisions of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10: 1675-1684
39. Ettinger DS, Wood DE, Aisner DL et al. NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 5.2017. March 16, 2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. (1 May 2017, date last accessed)
40. Baldwin DR, White B, Schmidt-Hansen M et al. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ 2011; 342: d2110
41. Lim E, Baldwin D, Beckles M et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65 (Suppl 3): iii1-iii27
42. Silvestri GA, Gonzalez AV, Jantz MA et al. Methods for staging nonsmall cell lung cancer diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e211S-e250S
43. Vernon J, Andruszkiewicz N, Schneider L et al. Comprehensive clinical staging for resectable lung cancer: clinicopathological correlations and the role of brain MRI. J Thor Oncol 2016; 11: 1970-1975
44. Brunelli A, Postmus PE, Preoperative functional evaluation of the surgical candidate. In HI Pass, D Ball, GV Scagliotti (eds), The IASLC Approach to Thoracic Oncology. Aurora, CO: IASLC 2014; 373-383
45. Yacoub WN, Meyers BF. Surgical resection in combination with lung volume reduction surgery for stage I non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2010; 22: 38-43
46. Falcoz PE, Conti M, Brouchet L et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007; 133: 325-332
47. Brunelli A, Varela G, Salati M et al. Recalibration of the revised cardiac risk index in lung resection candidates. Ann Thorac Surg 2010; 90: 199-203
48. Brunelli A, Cassivi SD, Fibla J et al. External validation of the recalibrated thoracic revised cardiac risk index for predicting the risk of major cardiac complications after lung resection. Ann Thorac Surg 2011; 92: 445-448
49. Lau KK, Rathinam S, Waller DA, Peake MD. The effects of increased provision of thoracic surgical specialists on the variation in lung cancer resection rate in England. J Thor Oncol 2013; 8: 68-72
50. Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17-41
51. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-bytwo factorial phase 3 study. Lancet Oncol 2015; 16: 187-199
52. Hong JC, Salama JK. Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?. Transl Lung Cancer Res 2016; 5: 126-133
53. Tucker SL, Liu A, Gomez D et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 2016; 119: 495-500
54. Harada H, Yamashita Y, Misumi K et al. Multidisciplinary team-based approach for comprehensive preoperative pulmonary rehabilitation including intensive nutritional support for lung cancer patients. PLoS One 2013; 8: e59566
55. Rosen JE, Keshava HB, Yao X et al. The natural history of operable nonsmall cell lung cancer in the National Cancer Database. Ann Thorac Surg 2016; 101: 1850-1855
56. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622
57. Veluswamy RR, Ezer N, Mhango G et al. Limited resection versus lobectomy for older patients with early stage lung cancer: impact of histology. J Clin Oncol 2015; 33: 3447-3453
58. Koike T, Kitahara A, Sato S et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer. Ann Thorac Surg 2016; 101: 1354-1360
59. Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol 2010; 5: 1583-1593
60. Nakamura K, Saji H, Nakajima R et al. A phase III randomized trial of lobectomy versus limited reection for for small-sized peripheral nonsmall cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010; 40: 271-274
61. Petrella F, Spaggiari L. The smaller the better: a new concept in thoracic surgery? Lancet Oncol 2016; 17: 699-700
62. ZhangW,Wei Y, JiangH et al. Video-assisted thoracoscopic surgery versus thoracotomy lymph node dissection in clinical stage I lung cancer: a metaanalysis and systemreview. Ann Thorac Surg 2016; 101: 2417-2424
63. Bendixen M, Jørgensen OD, Kronborg C et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol 2016; 17: 836-844
64. Rami-Porta R,Wittekind C, Goldstraw P, International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49: 25-33
65. Huang X,Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review andmeta-analysis. PLoS One 2014; 9: e109979
66. Chang JY, Liu YH, Zhu Z et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer 2013; 119: 3402-3410
67. Griffioen GH, Lagerwaard FJ, Haasbeek CJ et al. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol 2013; 107: 403-408
68. Artal Cortés A, Calera Urquizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015; 4: 191-197
69. NSCLC Meta-analyses Collaborative Group; Arriagada R, Auperin A, Burdett S et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two metaanalyses of individual patient data. Lancet 2010; 375: 1267-1277
70. Wakelee HA, Dahlberg SE, Keller SM et al. E1505: adjuvant chemotherapy +/-bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets. J Clin Oncol 2016; 34 (Suppl); abstr 8507
71. Butts CA, Ding K, Seymour L et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29-34
72. Salazar MC, Rosen JE, Wang Z et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol 2017; 3: 610-619
73. Strauss GM, Herndon JE 2nd,Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051
74. Lim E, Harris G, Patel A et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009; 4: 1380-1388
75. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and metaanalysis of individual participant data. Lancet 2014; 383: 1561-1571
76. Gilligan D, Nicolson M, Smith I et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-1937
77. Huang O, Li J, Sun Y et al. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis. Chest 2016; 149: 1384-1392
78. Tada H, Takeda K, Nakagawa K et al. Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer harboring activating EGFR mutation (WJOG6410L). J Clin Oncol 2012; 30 (Suppl); abstr TPS7110
79. National Cancer Institute, Lung Cancer. http://www.cancer.gov/types/ lung/research/alchemist (18 May 2017, date last accessed)
80. Lindberg K, Nyman J, Riesenfeld Källskog V et al. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT-the Nordic experience. Acta Oncol 2015; 54: 1096-1104
81. Verstegen NE, Lagerwaard FJ, Hashemi SM et al. Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol 2015; 10: 1195-1200
82. Louie AV, Palma DA, Dahele M et al. Management of early-stage nonsmall cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol 2015; 114: 138-147
83. Chen H, Louie AV, Boldt RG et al. Quality of life after stereotactic ablative radiotherapy for early-stage lung cancer: a systematic review. Clin Lung Cancer 2016; 17: e141-e149
84. Bahig H, Filion E, Vu T et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol 2016; 6: 367-374
85. Chen H, Senan S, Nossent EJ et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys 2017; 98: 245-246
86. Nambu A, Onishi H, Aoki S et al. Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors. BMC Cancer 2013; 13: 68
87. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 2014; 32: 2847-2854
88. Haasbeek CJ, Palma D, Visser O et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743-2747
89. Mauguen A, le Péchoux C, Saunders MI et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-2797
90. Cheung P, Faria S, Ahmed S et al. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer. NCIC CTG BR.25. J Natl Cancer Inst 2014; 106: dju164
91. Onishi H, Shirato H, Nagata Y et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011; 81: 1352-1358
92. Lagerwaard FJ, Verstegen NE, Haasbeek CJ et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: 348-353
93. Siva S, Ball D. Curing operable stage I non-small cell lung cancer with stereotactic ablative body radiotherapy: the force awakens. Oncologist 2016; 21: 393-398
94. Chang JY, Senan S, Paul MA et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-637
95. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
96. Samson P, Waters EA, Meyers B, PolitiMC. Shared decision making and effective risk communication in the high-risk patient with operable stage I non-small cell lung cancer. Ann Thorac Surg 2016; 101: 2049-2052
97. Hopmans W, Damman OC, Senan S et al. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer 2015; 15: 959
98. Chen F, Matsuo Y, Yoshizawa A et al. Salvage lung resection for nonsmall cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 2010; 5: 1999-2002
99. Neri S, Takahashi Y, Terashi T et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010; 5: 2003-2007
100. Allibhai Z, Cho BC, Taremi M et al. Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC. Eur Respir J 2012; 39: 1039-1042
101. Hamamoto Y, Kataoka M, YamashitaM et al. Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment. Jpn J Radiol 2012; 30: 671-675
102. Taira N, Kawabata T, Ichi T et al. Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells. Ann Thorac Surg 2014; 97: 2167-2171
103. Hamaji M, Chen F, Matsuo Y et al. Treatment and prognosis of isolated local relapse after stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: importance of salvage surgery. J Thorac Oncol 2015; 10: 1616-1624
104. Dickhoff C, Dahele M, Paul MA et al. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. Lung Cancer 2016; 94: 108-113
105. Verstegen NE, Maat AP, Lagerwaard FJ et al. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. Radiat Oncol 2016; 11: 131
106. Chang JY, Bezjak A, Mornex F. IASLC Advanced Radiation Technology Committee. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol 2015; 10: 577-585
107. Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013; 106: 276-282
108. Tekatli H, Haasbeek N, Dahele M et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with "ultracentral" nonsmall cell lung cancer. J Thorac Oncol 2016; 11: 1081-1089
109. Ambrogi MC, Fanucchi O, Dini P et al. Wedge resection and radiofrequency ablation for stage I non small cell lung cancer. Eur Respir J 2015; 45: 1089-1097
110. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for nonsmall cell lung cancer. Cochrane Database Syst Rev 2005; CD002142
111. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; 16: 672-681
112. Tsitsias T, Boulemden A, Ang K et al. The N2 paradox: similar outcomes of pre-and postoperatively identified single-zone N2a positive non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 45: 882-887
113. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450
114. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386
115. Pless M, Stupp R, Ris HR et al. Induction chemoradiation in stage IIIA/ N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386: 1049-1056
116. Eberhardt WE, Pöttgen C, Gauler TC et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33: 4194-4201
117. Senan S, Brade A,Wang LH et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016; 34: 953-962
118. Ahn JS, Ahn YC, Kim JH et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after con-current chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 2015; 33: 2660-2666
119. Vokes EE, Herndon JE II, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III nonsmall-cell lung cancer: cancer and leukemia group B. J Clin Oncol 2007; 25: 1698-1704
120. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-smallcell lung cancer. J Clin Oncol 2010; 28: 2181-2190
121. Warner A, Dahele M, Hu B et al. Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016; 94: 612-620
122. Kelly K, Altorki NK, Eberhardt WE et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 2015; 33: 4007-4014
123. Hu Y, McMurry TL, Isbell JM et al. Readmission after lung resection is associated with a 6-fold increase in 90-day postoperative mortality. J Thorac Cardiovasc Surg 2014; 148: 2261-2267
124. Pezzi CM, Mallin K, Mendez AS et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg 2014; 148: 2269-2277
125. Janssen-Heijnen ML, van Erning FN, de Ruysscher DK et al. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 2015; 26: 902-907
126. Lou F, Huang J, Sima CS et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145: 75-81. Discussion 81-82
127. Demicheli R, Fornili M, Ambrogi F et al. Recurrence dynamics for nonsmall-cell-lung cancer: effect of surgery on the develoment of metastases. J Thorac Oncol 2012; 7: 723-730
128. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90: 1335-1345
129. Ripley RT, McMillan RR, Sima CS et al. Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 2014; 98: 968-974
130. Voltolini L, Paladini P, Luzzi L et al. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg 2000; 18: 529-534
131. Hung JJ, Hsu WH, Hsieh CC et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009; 64: 192-196
132. Hamaji M, Allen MS, Cassivi SD et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 145: 683-690
133. Rosengart TK, Martini N, Ghosn P, Burt M. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg 1991; 52: 773-778
134. Spratt DE, Wu AJ, Adeseye V et al. Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for earlystage non small-cell lung cancer: implications for surveillance. Clin Lung Cancer 2016; 17: 177-183.e2
135. Huang K, Senthi S, Palma DA et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol 2013; 109: 51-57
136. Peulen H, Mantel F, GuckenbergerMet al. Validation of high-risk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016; 96: 134-141
137. De Leyn P, Dooms C, Kuzdzal J et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 3: 787-798
138. Lee TH, Marcantonio ER, Mangione CM et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-1049
139. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144